Vistagen 2027财年第二季净亏损收窄至1070万美元：研发开支降至660万美元
临床后期生物制药公司 Vistagen 于 2026 年 11 月 13 日在加利福尼亚州南旧金山公布 2027 财年第二季业绩，该财季截至 2026 年 9 月 30 日，并给出公司进展更新。
公司该季净亏损为 1070 万美元，上年同期为 1940 万美元，亏损同比收窄。业绩表列示的税前亏损为 1074 万美元，上年同期为 1942 万美元。
研发开支为 660 万美元，上年同期为 1590 万美元，同比大幅下降。该季总收入为 13.8 万美元，上年同期为 25.8 万美元，收入构成为再许可与其他收入。
按财年上半年计，公司净亏损为 2380 万美元，上年同期为 3450 万美元；上半年总收入为 161.4 万美元，上年同期为 50.2 万美元。
Vistagen 以鼻至脑神经环路为路径开发一类称为 pherines 的鼻内候选产品，属临床后期阶段公司。本季业绩中，收入规模仍小，业绩变动主要来自研发开支的同比变化与净亏损的收窄。
Vistagen Narrows Its Fiscal 2027 Second-Quarter Net Loss to 10.7 Million Dollars: Research and Development Expense Falls to 6.6 Million Dollars
Vistagen, a late clinical-stage biopharmaceutical company, reported financial results for its fiscal year 2027 second quarter ended September 30, 2026 in South San Francisco, California on November 13, 2026, and provided a corporate update.
Net loss was 10.7 million dollars for the three months ended September 30, 2026, compared with 19.4 million dollars for the same period in 2025. Loss before income taxes was 10.74 million dollars, against 19.42 million dollars a year earlier.
Research and development expense was 6.6 million dollars for the quarter, compared with 15.9 million dollars a year earlier. Total revenues were 138 thousand dollars, consisting of sublicense and other revenue, compared with 258 thousand dollars a year earlier.
For the first six months of the fiscal year, net loss was 23.8 million dollars, against 34.5 million dollars a year earlier, and total revenues were 1.61 million dollars, against 0.50 million dollars a year earlier. The six-month revenue figure is stated in the company's statements in thousands as 1,614 thousand dollars.
Vistagen is pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Revenue remained small in the quarter, and the change in results was driven mainly by the lower research and development expense and the narrower net loss.
来源：Vistagen Therapeutics
发布：GSM·美国（发布链接）
图片来源：图：药品生产线（Vistagen相关资料图）。Mohammdaon，CC BY-SA 4.0，Wikimedia Commons。 / Photo: 药品生产线. Mohammdaon, CC BY-SA 4.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
